Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan
TWYMEEG® Sales Performance and Forecast Update Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan A clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases characterized by metabolic pathophysiology, including metabolic…
BrightHeart Unveils Groundbreaking AI Results at SMFM 2025 Pregnancy Meeting, Transforming Prenatal Care
BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, recently presented two groundbreaking studies at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, which took place in Aurora, Colorado, on January 30th. These presentations,…
KORU Medical Systems Partners on Phase III Clinical Trial for New Nephrology Drug Indication
KORU Medical Systems Announces Strategic Collaboration for Phase III Clinical Trial on Expanded Drug Indication for Rare Renal Disorder KORU Medical Systems (NASDAQ: KRMD), a prominent medical technology company focused on innovative, patient-centric large volume subcutaneous infusion solutions, has announced…
Veradigm Completes Strategic Alternatives Review and Launches Operational Assessment
Veradigm Completes Strategic Alternatives Review and Announces Operational Assessment Veradigm® (OTCMKTS: MDRX), a prominent provider of healthcare data and technology solutions, has concluded its previously announced strategic alternatives review, aimed at maximizing stockholder value. The company’s Board of Directors (the…
TROPION-Lung12 Phase 3 Trial Launches to Assess DATROWAY® in Early-Stage NSCLC Patients at High Relapse Risk
TROPION-Lung12 Phase 3 Trial Begins to Evaluate DATROWAY® as Part of Adjuvant Treatment for High-Risk Early-Stage Non-Small Cell Lung Cancer Patients Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all…
Enveric Biosciences Receives Patent Approval for Lead Drug Candidate EB-003 from USPTO
Enveric Biosciences Announces Notice of Allowance for Patent on Lead Drug Candidate EB-003 Enveric Biosciences, a biotechnology firm focused on pioneering neuroplastogenic small-molecule therapeutics for mental health disorders, announced today that it has received a Notice of Allowance (NOA) from…
Science Exchange Unveils New Clinical Development Solution
Science Exchange Launches Clinical Development Solution to Revolutionize Clinical Trial Management Science Exchange, a leader in supplier orchestration solutions for the life sciences industry, has unveiled its new Clinical Development Solution. This platform aims to streamline and enhance the management…
Mirvie RNA Platform Identifies Unique Molecular Signal for Babies at Risk of Severe Growth Restriction
Mirvie, a leader in personalized and preventive care for pregnancy complications, recently presented groundbreaking findings at the Society for Maternal-Fetal Medicine annual meeting. The company revealed that its innovative RNA platform has identified a unique molecular signature that can predict…
Henry Schein Announces KKR Investment, Board Changes, and Preliminary 2025 Financial Outlook
Henry Schein Announces Strategic Investment by KKR, Board Changes, and Provides Financial Results and 2025 Guidance Henry Schein, Inc. (Nasdaq: HSIC), the world’s leading provider of health care solutions for office-based dental and medical professionals, today announced a strategic investment…
Cardinal Health Reports Q2 FY25 Results, Raises Outlook
Cardinal Health Reports Q2 FY25 Results, Raises Outlook Cardinal Health Reports Strong Q2 FY25 Results and Strategic Growth Moves Revenue and Earnings Overview Cardinal Health (NYSE: CAH) has reported a revenue of $55.3 billion for the second quarter of fiscal…
Aetna Better Health of Illinois Adds New Benefits to Tackle Health Disparities
Aetna Better Health of Illinois, a CVS Health company (NYSE: CVS), has introduced three new lifestyle benefits designed to support its Medicaid members enrolled through the HealthChoice Illinois program. These benefits aim to reduce barriers to a healthier lifestyle by…
Cigna Group Announces Q4 & Full-Year 2024 Results, Sets 2025 Outlook, and Raises Dividend
Cigna Group Reports Strong 2024 Financial Results, Sets 2025 Outlook, and Announces Dividend Increase Global health company The Cigna Group (NYSE: CI) has released its financial results for the fourth quarter and full year 2024, demonstrating continued strength in Evernorth…